Physiol Rep by Nemska, S (author) et al.
ORIGINAL RESEARCH
Revascularization of the graft in obliterative bronchiolitis
after heterotopic tracheal transplantation
Simona Nemska, Francois Daubeuf & Nelly Frossard
Laboratoire d’Innovation Therapeutique, Unite Mixte de Recherche 7200, Centre National de la Recherche Scientifique-Universite de Strasbourg
and Laboratoire d’Excellence MEDALIS, Faculte de Pharmacie, Illkirch, France
Keywords
Lung transplantation.
Correspondence
Nelly Frossard, Laboratoire d’Innovation
Therapeutique, Unite Mixte de Recherche
7200, Centre National de la Recherche
Scientifique-Universite de Strasbourg and
LabeX Medalis, Faculte de Pharmacie, 74
Route du Rhin, 67400 Illkirch, France.
Tel: +33-368-854196
Fax: +33-368-854309
E-mail: nelly.frossard@unistra.fr
Funding Information
We thank the French Cystic Fibrosis
Association “Vaincre la Mucoviscidose”
(PRTP-08), the Alsace region and the
Laboratory of Excellence MEDALIS (LABEX
ANR-10-LABX-0034_Medalis) for funding.
Received: 2 October 2015; Revised: 21
December 2015; Accepted: 23 December
2015
doi: 10.14814/phy2.12690
Physiol Rep, 4 (4), 2016, e12690,
doi: 10.14814/phy2.12690
Abstract
Obliterative bronchiolitis is the principal long-term problem for lung trans-
plant patients. One of the simplest and most reproducible animal models of
obliterative bronchiolitis is heterotopic tracheal transplantation in subcuta-
neous tissue, where the graft is not primarily vascularized. We demonstrate
here the rapid graft revascularization and the kinetics of expression of its
angiogenic and lymphatic factors. We performed iso- and allotracheal trans-
plantations harvested on day 0–21. The number of functional blood vessels,
quantified after intravenous biotinylated dextran administration, increased
from D0 (0 for both iso- and allografts) to D21 (44  8 vessels/mm2 in iso-
grafts and 22  3 in allografts, P < 0.001 for both vs. D0). VEGF mRNA
expression assessed by qPCR peaked on D1 (4.3-fold increase in isografts and
4.0-fold in allografts, P < 0.0001 for both vs. D0), but receded thereafter.
Angiopoietin-1, involved in the maturation of the neoformed vessels,
increased later on, by 6.2-fold (P < 0.05) in isografts and 11.5-fold in allo-
grafts (P < 0.001) by D21, and angiopoietin-2 by 7.8-fold in isografts
(P < 0.05) and 13.8-fold in allografts (P < 0.01). Although always present in
the iso- and allografts, there were significantly more and larger LYVE1+ lym-
phatic vessels at D21 in allografts than in isografts. Thus, we demonstrate that
tracheal grafts are rapidly revascularized by functional blood and lymphatic
vessels, due to early VEGF and subsequent angiopoietins expression, which is
a new advantage of this model, in addition to its ease of use, reproducibility,
and viability in the absence of immunosuppressive treatment.
Introduction
Lung transplantation (LT) is currently the only possible
treatment for patients with end-stage pulmonary diseases
such as cystic fibrosis, COPD, or idiopathic pulmonary
fibrosis. The main long-lasting problem after LT remains
the chronic lung allograft dysfunction (CLAD), including
three phenotypes of persistent decline in pulmonary func-
tion: neutrophilic reversible allograft dysfunction (NRAD)
which can be attenuated by azithromycin treatment;
restrictive allograft syndrome (RAS), characterized by
parenchymal infiltrates; and the bronchiolitis obliterans
syndrome (BOS) with evidence of airway obliteration by
inflammatory and fibroproliferative tissue observed in
transbronchial biopsies, referred to as obliterative bron-
chiolitis (OB) (Suwara et al. 2014; Verleden et al. 2014).
BOS occurs in around 50% of patients after the fifth year
posttransplantation (Girgis et al., 1996; Hayes, 2011). It is
a multifactorial process including primarily alloimmune
T-cell reactivity, human leukocyte antigen (HLA)
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antibody-mediated rejection, autoimmune reactions, and
environmental stress responses (Neuringer et al. 2005;
Belperio et al. 2009; Grossman and Shilling 2009; Todd
and Palmer 2011). No effective treatment for this post-
graft complication is yet available.
Although the orthotopic lung transplantation in
rodents seems to be the most relevant model for the
study of OB in laboratory animals, it also shows clear dis-
advantages. Aside from its complexity to be performed in
small animals, the allograft appears as edematous and
necrotic when no immunosuppressive treatment is added
in order to overcome the acute rejection (Yasufuku et al.
2002; Okazaki et al. 2007), decreasing the number of allo-
grafts developing OB lesions to 30% with gross variability
(Zhang et al. 2008; De Vleeschauwer et al. 2012). Jun-
graithmayr et al. (2010) developed an immunosuppressive
regimen with cyclosporine and rapamycin allowing the
development of chronic rejection in 80% of the allografts
in the rat, but the signs of fibroproliferation occurred
only after 84 days posttransplantation and without airway
obliteration. Considering the heterogeneity in the time
period and in the obliterative signs, this model of chronic
rejection after orthotopic lung transplantation in rodents
seems of difficult use for proof-of-concept studies for
novel OB treatments. More simple but reproducible mod-
els for first-line proof-of concept studies in OB may be
used more efficiently. Such model is the heterotopic tra-
cheal transplantation (HTT) in the subcutaneous tissue of
an HLA-mismatched recipient (Hertz et al. 1993). HTT is
an easy-to-perform and reproducible model that develops
characteristics of OB, that is, inflammatory cell infiltra-
tion and fibroproliferative graft obstruction, within
21 days. The process involves an early inflammatory
phase with initial epithelial injury, followed by impaired
epithelial regeneration and apoptosis in allografts as well
as infiltration by alloreactive CD4+ and CD8+ T cells
(Szeto et al. 2000; Neuringer et al. 2002; Richards et al.
2003, 2004). This inflammatory phase is followed by a
fibroproliferative one, mediated by growth factors such as
transforming growth factor b, platelet-derived growth fac-
tor, and basic fibroblast growth factor; it leads to fibrob-
last and myofibroblast proliferation and collagen
deposition and subsequently to tracheal obstruction (Al-
Dossari et al. 1995; Aris et al. 2002; Ramirez et al. 2004).
Because the transplantation is in a heterotopic position,
this model allows the study of the graft lesions over time,
and avoids compromising the animal’s life. As any animal
model of a human disease, HTT has some disadvantages,
most especially that the transplanted trachea is not func-
tional, that is, in direct contact with air, and cannot be
said to reflect the overall lung environment. In addition,
the nonvascularization of the tracheal graft has been men-
tioned as its primary disadvantage (Grove et al. 2011;
Neuringer et al. 2002; Oyaizu et al. 2003; Okada et al.
2004; Batirel et al. 2005; Maruyama et al. 2005; Zhou
et al. 2005; McDyer 2007; Xu et al. 2008; Lau et al. 2009;
Sato et al. 2009; Shah et al. 2009). A few studies have
suggested that neovascularization of the graft might occur
in HTT (Hertz et al. 1993; Nusair et al. 2005; McDyer
2007; Shah et al. 2009), but no histological evidence of
the presence or functionality of blood vessels has been
reported. Nor has lymphatic revascularization of the graft
in this HTT model been shown, although lymphatic vas-
culature is necessary for the trafficking of lymphocytes
and antigen-presenting cells from the tissue to the lymph
node that is essential for the immune response of graft
rejection (Zawieja 2005; Choi et al. 2012).
We describe here the rapid revascularization of the
graft by functional blood and lymphatic vessels after
HTT, and provide histological evidence of this functional
revascularization. Finally, we report the expression over
time of angiogenic and lymphatic factors – VEGF (vascu-
lar endothelial growth factor), angiopoietin-1 (Ang1) and
-2, and podoplanin (Pdpn) – in the increasingly obliter-
ated graft.
Methods
Animals
Animals were purchased from Janvier (Le Genest-Saint-
Isle, France). Nine-week-old male Balb/cJ mice (H-2Kd)
served as donors for iso- and allografts and as recipients
for isografts. Nine-week-old male C57BL/6J mice (H-2Kb)
were used as recipients for allografts. The animals were
maintained on a 12/12-h light/dark cycle, with food and
water available ad libitum. All animals received humane
care in compliance with the guidelines formulated by the
French Ministry of Agriculture and of Higher Education
and Research, and all procedures were performed in
accordance with the European Community Council
Directive of November 24, 1986 (86/609/EEC) and the
French laws (agreement number 2015060415569684 APA-
FiS#768).
Heterotopic tracheal transplantation
Donors were anesthetized with ketamine (154 mg/kg)
(Imalgene, Merial) and xylazine (10 mg/kg) (Rompun,
Bayer) in saline, administered intraperitoneally, and
killed. Tracheas were procured after perfusion with EDTA
2.6 mmol/L in saline and immediately placed in ice-cold
PBS. Recipient mice were anesthetized by intraperitoneal
administration of ketamine (51.4 mg/kg) and xylazine
(3.3 mg/kg) in saline. Two subcutaneous pockets were
dissected on the back of the mouse neck, and a half
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trachea from one donor was transplanted in one pocket
and a half trachea from another donor in the other.
Pockets were sutured with 5.0 silk suture (Silkam). Mice
were maintained for up to 21 days after transplantation.
No immunosuppressant treatment was used. Transplanted
tracheal grafts were harvested on day 0 (D0, at 1 h post-
transplantation), D1, D3, D7, or D21, from mice deeply
anesthetized by intraperitoneal injection of ketamine
(154 mg/kg) and xylazine (10 mg/kg) in 0.1 mL saline,
and perfused with EDTA 2.6 mmol/L in saline.
Histology and immunohistochemistry
Harvested grafts (n = 6 per group) were fixed in
paraformaldehyde 4% for 24 h, and paraffin-embedded
after successive lavages in ethanol (70–100%), followed by
incubation in HistoClear (National Diagnostics, UK) and
in paraffin at 60°C. Three levels (separated by 76 lm) of
4 lm transversal sections were cut per trachea and
mounted on Superfrost glass slides (Fisher Scientific,
France). After deparaffinization in xylene and successive
rehydration, sections were treated with citrate buffer
(10 mmol/L sodium citrate, 0.05% Tween 20) for antigen
unmasking, and with endogenous peroxidase and alkaline
phosphatase blocking reagent (Dako, S2003).
Tracheal sections were used for immunohistochemistry
of the endothelial blood vessel CD31 marker (Goat poly-
clonal antibody, Santa Cruz, sc1506, 1:3000) and the lym-
phatic vessel LYVE1 (Lymphatic Vessel Endothelial
Hyaluronan Receptor 1) marker (Rabbit polyclonal anti-
body, Abcam, ab14917, 1:1000), and for nuclei labeling
with Neutral Red (Sigma, 72210, 1 g/L). Secondary anti-
bodies were purchased from Jackson Laboratory and used
at 1:500.
Vessel counts were performed (1) on tracheal tissue in
the epithelial and subepithelial layer as well as around the
cartilage for iso- and allografts; and (2) within the fibro-
proliferative tissue for allografts. Sections were observed
on a Leica DM4000B microscope and analyzed with an
Olympus DP72 camera with CellSensDimension software.
The size of the CD31 vessels and of Lyve-1 lymphatic ves-
sels was measured with ImageJ software by their surface.
Hematoxylin–eosin staining was performed on transversal
tracheal sections from D0 to D21 in iso-and allografts,
and the epithelial loss was quantified (ImageJ).
Dextran–biotin administration
On the day of graft harvest, the anesthetization took place
10 minutes after the intravenous administration in the
tail vein of dextran-biotin (Sigma, 14402; 80 mg/kg in
50 lL). Four-lm tracheal sections (n = 6 per group)
from dextran-biotin-treated animals were incubated
directly with streptavidin peroxidase (Sigma, E2886,
1:500). Vessels were revealed with 3,30-diaminobenzidine,
and nuclei were stained in a solution of Methyl Green
(Sigma, 198080, 5 g/L, pH 4.2).
RNA extraction, RT-PCR, and qPCR
For mRNA quantification by RT-qPCR in tracheas har-
vested at D0, D1, D3, D7, and D21, total RNA was
extracted from pools of four half-tracheas (n = 6 pools
per group) with the RNAeasy Micro Kit (Qiagen) and
quantified on a Nanodrop. One lg of RNA was reverse-
transcribed with mMLV reverse transcriptase (Promega).
cDNA was used for qPCR, with the Applied Biosystem
primers for VEGF isoform A (Mm01281449_m1), HIF1a
(Mm00468869_m1), angiopoietin-1 (Mm00456503_m1),
angiopietin-2 (Mm00545822_m1), podoplanin (Mm00
494716_m1), and HPRT1 (Mm01545399_m1) as a house-
keeping gene. An ABI Prism 7000 thermocycler per-
formed 40 cycles of qPCR for each gene. Expression of
the mRNA of the gene of interest was referenced to
HPRT1 (hypoxanthine phosphoribosyltransferase 1)
expression (2DCt) and calibrated to the D0 values
(2DDCt).
Statistical analysis
Data are expressed as means  SEM. Statistical analyses
were performed with one-way ANOVA and then Bonfer-
roni’s post hoc test for comparison of selected data pairs.
Differences were considered significant when P < 0.05.
Results
Vascularization of tracheal and
fibroproliferative tissues after heterotopic
tracheal transplantation
Immunolabeling of tracheal sections for the endothelial
marker CD31 showed CD31+ endothelium both in iso-
and allografts. As Figure 1A shows, CD31+ vessels were
located in the subepithelial layer of tracheas and in the
tissue surrounding the cartilaginous rings. From D0 to
D21 after transplantation, the number of CD31+ blood
vessels increased progressively in tracheal tissue in allo-
grafts (Fig. 1B), from 14  1 at D0 to 48  10 vessels/
mm2 at D21 (P < 0.01 vs. D0), and in isografts, from
15  4 at D0 to 34  9 vessels/mm2 at D21 (P < 0.05
vs. D0) (Fig. 1B). This number did not differ significantly
between these graft types. We also observed CD31+ blood
vessels within the fibroproliferative tissue, obstructing the
tracheal lumen in allografts on D21 (70  15 vessels/
mm2) (Fig. 1B). We analyzed the size of the CD31 vessels
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Figure 1. Vascularization of iso- and allografts after heterotopic tracheal transplantation. Paraffin-embedded sections of the tracheal grafts
were immunostained for the endothelial marker CD31. (A) CD31+ vessels were visualized in the tracheal tissue (D0–D21, iso- and allograft) and
in the fibroproliferative tissue obstructing the tracheal lumen (D21, allograft) after streptavidin-peroxidase revelation and stained blue with
Histogreen (dark arrows). Cell nuclei are colored red after Neutral Red staining. Gx400. (B) Counts of CD31+ vessels per mm2 in the tracheal
tissue (Tr; Black and white blocks). The count of CD31+ vessels per mm2 in the fibroproliferative tissue (Fp; Pattern block) is presented for the
D21 allograft. Three levels of sections were counted for each trachea. Data represent mean values (blocks)  SEM (bars) (n = 6). *P < 0.05,
**P < 0.01 compared to D0. (C) The CD31 vessel size was quantified by ImageJ software and represented as mm2 surface from D0 to D21 in
both iso- and allografts. (D) Kinetics of the epithelial regeneration in isografts and of the epithelial loss in allografts. Hematoxylin and eosin
staining of transversal cuts of tracheas iso- (left) and allografts (right) at D0, D3 D7 and D21 after transplantation.
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in iso- and allografts from D0 to D21, but we did not
find any significant modification of the vessel size
(Fig. 1C). CD31+ vessels are of size between 10 lm2 and
120 lm2.
The rate of epithelial loss was quantified in iso- and
allografts at D0, D3, D7, and D21 posttransplantation on
hematoxylin–eosin stained sections to characterize and
validate the OB model (Fig. 1D). In isografts, the tracheal
epithelium is degraded (44  12% of epithelial loss) at
D3, and further re-epithelialized at D7 (only 5  2% of
epithelial loss) and D21 (0 %). In allografts by contrast,
the epithelium is degraded by D3 (83  7%), and
remains further degraded at D7 (67  8%) and D21
(100%) (Table 1).
Functionality of blood vessels vascularizing
the graft
To demonstrate the functionality of the blood vessels, we
labeled them in vivo with dextran, which binds to blood
vessel endothelium. Dextran-labeled blood vessels were
shown in the subepithelial layer and in the tissue sur-
rounding cartilaginous rings in both iso- and allografts
(Fig. 2A). Figure 2B presents the labeled vessel counts at
each time point. As expected, there were no functional
blood vessels on D0 in either graft type. The number
increased progressively from D3 to D21: 9  2 vessels on
D3 to 44  8 on D21 (P < 0.001 vs. D0) in isografts and
5  1 on D3 to 22  3 on D21 (P < 0.01 vs. D0) in
allografts. These increases suggest that an angiogenic pro-
cess occurs after transplantation. The number of dextran-
labeled vessels at D21 also differed significantly between
isografts and allografts (P < 0.001) (Fig. 2B). Addition-
ally, we observed dextran-labeled vessels within the fibro-
proliferative tissue of allografts (34  9 vessels/mm2),
indicating that the OB model is vascularized with func-
tional blood vessels (Fig. 2B).
Expression of angiogenic factors in the
graft
To understand the molecular mechanisms underlying our
histological observation of the increased vascularization in
the grafts posttransplantation, we analyzed mRNA expres-
sion of the angiogenic factors VEGF, angiopoietin-1
(Ang1), and -2 (Ang2).
VEGF is an angiogenic factor that promotes angiogene-
sis and neovascularization in tissue. VEGF mRNA expres-
sion peaked at D1 in iso- (4.3-fold increase vs. D0,
P < 0.0001) and allografts (4.0-fold increase vs. D0,
P < 0.001) (difference between iso- and allografts not sig-
nificant) (Fig. 3A). It then decreased progressively (D3,
D7), with levels lower on D21 than on D0 (Fig. 3A). As
VEGF expression is reported as modulated by hypoxia,
we also analyzed the expression of the hypoxia transcrip-
tion factor HIF1a, but did not observe any increase on
D1 when hypoxia is occurring (Fig. 3B). Interestingly,
HIF1a shows a trend, although nonsignificant, to increase
on D7, when the vascularization is re-established both in
iso- and allografts (Fig. 3B).
Ang1 is an angiogenic marker that plays an important
role in blood vessel remodeling and maturation and
thereby promotes blood vessel stability. We observed
increased mRNA expression of Ang1 in iso- and allografts
from D7 posttransplantation, by 7.4-fold in isografts com-
pared to D0 (P < 0.01) and 4.4-fold in allografts (NS vs.
D0) (Fig. 3C); at D21, these fold-increases were 6.2 in
isografts (P < 0.05) and 11.5 in allografts (P < 0.001),
compared to D0 (Fig. 3C). This high expression of Ang1
at a stage when VEGF has fallen below baseline values
suggests that Ang1 might be important in the OB model
for stabilization of the blood vessels newly formed under
the primary action of VEGF. Ang2 mRNA expression
increased significantly in allografts from D7 to D21: 9.7-
fold at D7 (P < 0.05 vs. D0) and 11.3-fold at D21
(P < 0.01 vs. D0) (Fig. 3D). Here again, this late expres-
sion in allografts suggests that Ang2 has a role in the vas-
cular remodeling associated with the allogeneic
fibroproliferation. In isografts, the levels of mRNA expres-
sion remained rather stable from D3 to D21: a 7.5-fold
increase at D3 (NS vs. D0) versus 7.8-fold at D21
(P < 0.05 vs. D0).
Lymphatic vessels vascularize the OB model
Immunostaining for the lymphatic vessel marker LYVE1
(Fig. 4A) showed LYVE1-labeled vessels in tracheal tissue
in the subepithelial layer of both iso- and allografts, as
well as within the fibroproliferative tissue in allografts at
D21. Their number increased in tracheal tissue (Tr) from
5  4 at D0 to 23  4 vessels/mm2 at D21 in isografts
(P < 0.01) and from 7  4 at D0 to 16  5 at D21 in
allografts (NS) (Fig. 4B). In addition, lymphatic vessels
were observed in the fibroproliferative tissue (Fp)
obstructing the allografts (38  9 vessels/mm2) and are
represented as a separate block (D21 Fp) on Figure 4B.
Lymphatic vessel size was analyzed in iso- and allografts
Table 1. Quantification of the percentage of degraded epithelium
in iso- and allografts at D0, D3, D7 and D21 (Mean  SD).
% degraded epithelium D0 D3 D7 D21
Isograft 0 44  12 5  2 2  1
Allograft 0 83  7 67  8 100
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in the tracheal and fibroproliferative tissue in the whole
tracheal sections in each group (D0, D3, D7, D21). Ves-
sels of 0–30, 30–300, and >300 lm2 were counted
(Fig. 4D). Vessels of 30–300 lm2 were observed in iso-
grafts, mostly at D3 (2.5  0.6 vessels/section, P < 0.05
vs. D0), whereas in allografts any significant increase
occurred until D21 (3.6  1.1 vessels/section, P < 0.01
vs. D0) (Fig. 4C). The largest vessels (>300 lm2) were
totally absent at D21 from isografts, but there were a few
of these very large vessels at D21 in allografts
(0.8  0.4 vessels/section) (Fig. 4D). For lymphatic ves-
sels as a whole (Total on Fig. 4D), a significant increase
in the total number of lymphatic vessels – including tra-
cheal and fibroproliferative tissue – occurred late in allo-
grafts, on D21 (5.6  1.4 vessels/section, P < 0.001 vs.
D0), at the same time that lymphatic vessels developed in
the fibroproliferative tissue (Fig. 4B). In the isografts, in
contrast, the total number of lymphatic vessels increased
early, on D3 (3.2  0.8 vessels/section, P < 0.05) and
decreased thereafter to values close to those of controls
(Fig. 4D).
We also quantified the expression of podoplanin
(Pdpn), a mucin-type transmembrane glycoprotein specif-
ically expressed by lymphatic endothelial cells. mRNA
expression peaked on D7, similarly in iso- and allografts
(17- and 16-fold increase vs. D0, respectively, P < 0.001)
(Fig. 4C). No significant difference was found between
the D0 levels of Pdpn mRNA expression (2DCt values) in
isografts (2.2  1.2) and allografts (0.8  0.2).
Discussion
The murine heterotopic tracheal allotransplantation HTT
model is a common model for studying obliterative bron-
chiolitis or OB development after transplantation. The
primary advantages include that it allows the detailed
study of the mechanisms of inflammation and fibroprolif-
eration associated with the progressive obstruction of the
airways, as in this heterotopic position it is no longer life
threatening. In human lung transplantation, because of
the direct contact of the transplanted lung with the air
and along with the classical immunosuppressive post-
transplantation treatment, patients are often subjects to
viral and bacterial infections. Neutrophils are in this case
infiltrating the lung and we observe the so-called NRAD
form of CLAD (discussed in the Introduction), which
cannot be modeled by the classic HTT. Other signal pre-
sent in humans and which is cause for OB is the gastro-
esophageal reflux. Although we state that HTT is a good
and not aggressive model for first proof-of-concept
studies of OB treatment, and we bring here a new advan-
tage, which is the revascularization of the graft. The non-
Isograf Allogra
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Figure 2. Functional vascularization of iso-and allografts after heterotopic tracheal transplantation. Biotinylated dextran (80 mg/kg) was
administered IV before tracheal harvest. (A) Blood vessels were visualized in the tracheal tissue (D0–D21, iso- and allograft) and in the
fibroproliferative tissue obstructing the tracheal lumen (D21, allograft) after streptavidin-peroxidase incubation of the paraffin-embedded
sections and were then stained brown with 3,30-Diaminobenzidine (dark arrows). Cell nuclei are colored blue after Methyl Green staining.
Gx400. (B) Count of dextran+ vessels per mm2 in the tracheal tissue (Tr; Black and white blocks). The count of Dextran+ vessels per mm2 in the
fibroproliferative tissue (Fp; Pattern block) is presented for the D21 allograft. Three levels of sections were counted for each trachea. Data
represent mean values (blocks)  SEM (bars) (n = 6). ***P < 0.001 compared to D0.
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vascularization of the tracheal graft has been mentioned
earlier as a primary disadvantage of the model (Grove
et al. 2011; Neuringer et al. 2002; Oyaizu et al. 2003;
Okada et al. 2004; Batirel et al. 2005; Maruyama et al.
2005; Zhou et al. 2005; McDyer 2007; Xu et al. 2008; Lau
et al. 2009; Sato et al. 2009; Shah et al. 2009). However,
processes occurring after HTT, such as the infiltration of
inflammatory cells into the allograft and the re-epitheliali-
zation of the isograft, nonetheless suggest potent functional
graft revascularization. A few reports provide evidence that
the graft is revascularized (Belperio et al. 2005; Fan et al.
2013), but no one has ascertained the functional blood and
lymphatic vasculature in the graft and in the obliterative
trachea. This was the aim of our study.
To do so, immunostaining for the marker of blood
endothelial cells CD31 (Zhao et al. 2010) shows blood
vessels in the grafted trachea, located within the subep-
ithelial layer and around the cartilaginous rings. We
report a significant increase in the number of CD31+ ves-
sels from D0 to D21 in both iso- and allografts, suggesting
occurrence of posttransplantation angiogenesis. This is in
contrast to the report by Zhao et al. (2010) of CD31-
immunostaining in allografts (Balb/c to C57BL/6), with
no increase in terms of densitometric units between D3
and D21, whereas we clearly quantified an objective
increased number of CD31-labeled blood vessels in the
grafted tracheal tissue. Another study (Batirel et al. 2005)
reported, consistently with our results, no difference in
the number of CD31+ vessels from D14 to D28 in iso-
and allografts but included no comparison to an earlier
time point posttransplantation. Another important find-
ing of our study is the presence of CD31+ vessels within
the obstructive fibroproliferative tissue in allografts at
D21, that is, in the OB model. This indicates that the
fibroproliferative tissue is highly vascularized, and suggests
that fibrosis and vascularization occur simultaneously.
These results obtained in murine heterotopic tracheal allo-
grafts are consistent with data from lung transplant
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Figure 3. Relative expression of mRNA of angiogenic genes in tracheal grafts. qPCR was performed with the Applied Biosystem Gene
Expression Assay in pools of four half-tracheas for each time point (n = 6 pools). The results are calculated by the DDCt method (DDCt = DCt
sample  DCt calibrator, where DCt is the mean value at D0 iso- or allograft). (A) Quantification of the expression of VEGF mRNA in the
grafts. ****P < 0.0001 compared to D0. No significant difference of the D0 levels of VEGF mRNA expression (2DCt values) between isografts
(6.3  0.7) and allografts (8.8  1.6). (B) Quantification of the expression of HIF1a mRNA in the grafts. No significant difference of the D0
levels of HIF1a mRNA expression (2DCt values) between isografts (2.2  1.1) and allografts (1.5  0.5). (C) Quantification of the expression of
angiopoietin-1 mRNA in the grafts. ***P < 0.001, **P < 0.01, *P < 0.05 compared to D0. No significant difference of the D0 levels of Ang1
mRNA expression (2DCt values) between isografts (1.3  0.3) and allografts (2.2  1.0). (D) Quantification of the expression of angiopoietin-2
mRNA in the grafts. **P < 0.01, *P < 0.05 compared to D0. No significant difference of the D0 levels of Ang2 mRNA expression (2DCt values)
between isografts (2.1  1) and allografts (2.6  1.5).
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patients with OB reporting that the number of CD31-
labeled vessels in small airways increases with airway
obliteration (Luckraz et al. 2004).
We then sought to demonstrate the functionality of
these CD31+ vessels through their in vivo labeling by dex-
tran-biotin, which binds to the lectin structures of the vas-
cular endothelium (Gonzalez-Castillo et al. 2003), and
allows to follow the functional vascularization of the graft
over time. As expected, our results show no functional
blood vessels at D0 (i.e., at 1 h posttransplantation) in iso-
and allografts, as no primary vasculature was reconnected
at transplantation. We then show the functional revascu-
larization of the tracheal tissue as early as D3, which
increases over time up to D21 both in iso- and allografts.
In accordance with the CD31 labeling, the functional dex-
tran-labeled vessels were mainly located within the subep-
ithelium both in iso- and allografts. The number of
dextran-labeled vessels was twice as high in isografts as in
allografts on D21, suggesting the allogeneicity may affect
posttransplant angiogenesis and vascular growth. This is
the first demonstration to our knowledge of the kinetics of
functional blood vessels in the tracheal graft.
In addition, we show in isografts that functional revas-
cularization occurs progressively in parallel with epithelial
Isogra Allogra
D0
D3
D7
D21
A B C
D
Figure 4. Lymphatic vascularization after heterotopic tracheal transplantation. Paraffin-embedded sections of the tracheal grafts were
immunostained for the lymphatic marker LYVE1. (A) LYVE1+ vessels are visualized in the tracheal tissue (D0–D21, iso- and allograft), and in the
fibroproliferative tissue obstructing the tracheal lumen (D21, allograft) after streptavidin-peroxidase revelation; they are stained blue with
Histogreen (dark arrows). Cell nuclei are colored red after Neutral Red staining. Gx400. (B) Count of LYVE1+ vessels per mm2 in the tracheal
tissue (Tr; Black and white blocks). The count of LYVE1+ vessels per mm2 in the fibroproliferative tissue (Fp; Pattern block) is represented for the
D21 allograft. Three levels of sections were counted for each trachea. Data represent mean values (blocks)  SEM (bars) (n = 6). **P < 0.01,
*P < 0.05 compared to D0. (C) Expression of the lymphatic marker podoplanin in the graft after heterotopic tracheal transplantation. qPCR
was performed with the Applied Biosystem Gene Expression Assay in pools of four half-tracheas for each time point (n = 6 pools). Results are
calculated by the DDCt method (DDCt = DCt sample  DCt calibrator, where DCt is the mean value on D0 for the iso- or allograft).
*P < 0.05, ****P < 0.0001 compared to D0. (D) Measurement of the surface area of the lymphatic vessels. The surface area (lm2) of
lymphatic vessels LYVE1+ in the entire tracheas was measured with ImageJ software. The figure presents the mean value of the number of
lymphatic LYVE1+ vessels/section SEM (bars), counted for each time point for iso- and allografts. Vessels are grouped as three sizes: 0–30,
30–300, >300 lm2 are shown. Three levels of sections were counted for each trachea. *P < 0.05, **P < 0.01, ***P < 0.001 compared to D0.
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regeneration, which is almost complete by D21 (Neurin-
ger et al. 2002; Lau et al. 2009). We confirm in allografts
that the alloreaction prevents epithelial regeneration, as
epithelium is still degraded on D7; rather than epithelial
regeneration, inflammatory cell infiltration occurs, fol-
lowed by fibroproliferation, which is nearly complete by
D21 (Hertz et al. 1993; Neuringer et al. 2002; KleinJan
et al. 2008; Lau et al. 2009). We are the first to demon-
strate, however, that OB in allografts is associated with
fewer dextran-labeled functional blood vessels in the tra-
cheal tissue compared with isografts.
We next investigated the expression of the angiogenic
factors VEGF, Ang1, and Ang2, during revascularization
of the graft and vascular remodeling in the allografts.
VEGF acts on the maintenance of normal vascularity in
the lung (Voelkel et al. 2006). The peaking of VEGF
expression on D1 as compared to D0 both in iso- and
allografts suggests rapid signaling for angiogenesis after
transplantation. VEGF decreased thereafter, from D3 to
D21. We measured in parallel the expression of the
hypoxia-inducible transcription factor HIF1a controlling
the VEGF gene (Forsythe et al. 1996). HIF1a expression
was not modified at D1 when VEGF peaked, in contrast
to the reported increase in HIF1a protein expression in a
mouse model of orthotopic tracheal allotransplantation
(Jiang et al. 2011). This does not exclude, however, the
possibility of stabilization of the HIF1a subunit and sub-
sequent activation of the expression of VEGF gene in our
model (Pages and Pouyssegur 2005; Semenza et al. 2000;
Mura et al. 2004; Kugathasan et al. 2005).
The angiopoietins (Ang1 and Ang2) are other impor-
tant angiogenic factors. Their expression significantly
increased later in our model, on D21 in iso- and allo-
grafts compared to D0, that is, after VEGF expression has
ended. Ang1 and Ang2 have highly similar sequences and
are both ligands of the Tie2 receptor (tunica intima
endothelial tyrosine kinase 2), expressed by vascular
endothelial cells (Fiedler et al. 2003; Brindle et al. 2006;
Kumpers et al. 2010), but distinct functional and cell-sig-
naling characteristics. Ang1 is reported to play a role in
the maturation and stabilization of newly formed blood
vessels through activation of Tie2 autophosphorylation
and intracellular signaling; it induces endothelial cell
migration, sprouting, and tube formation (Koblizek et al.
1998; Witzenbichler et al. 1998; Hayes et al. 1999; Jones
et al. 1999; Kwak et al. 1999). A late increased expression
of Ang1 is observed in our study both in iso- and allo-
grafts. We propose this allows maturation of the blood
vessels initially newly formed under the influence of
VEGF, stabilizing their structural integrity (Augustin et al.
2009). This is consistent with reports of the chemotactic
properties of Ang1 (Witzenbichler et al. 1998; Metheny-
Barlow et al. 2004), that might play a role in the
increased Ang1 expression we observed in allografts, sig-
nificantly higher than in isografts at D21.
In contrast, Ang2 prevents Ang1 binding to Tie2,
thereby inhibiting Tie2 autophosphorylation, and func-
tions as a natural Tie2 antagonist to regulate vascular
development (Maisonpierre et al. 1997). Hence, Ang2 is
required for normal vascular remodeling (Gale et al.
2002) and vessel regression, especially in the absence of
VEGF (Holash et al. 1999; Lobov et al. 2002; Brindle
et al. 2006; Augustin et al. 2009). Ang2 was also expressed
late as compared to VEGF in the grafts. In isografts, Ang2
expression appears fairly stable from D3 to D21, whereas
it increases progressively in allografts from D7 to D21.
This is also consistent with aberrant angiogenesis reported
in lung biopsies from BOS patients (Belperio et al. 2005).
This may be related to Ang2’s role in vascular remodeling
and angiogenesis regression, as reported in lung tumors
where blocking Ang2 improves the quality of junctions
between endothelial cells (Holopainen et al. 2012). Thus,
we hypothesize that allogeneicity helps to promote the
expression of Ang2 in allografts, that leads to vascular
remodeling, and thus slows the vascularization process.
Endothelial and bronchial epithelial cells are angiopoietins
producing cells (Mura et al. 2004). In isografts which are
re-epithelialized at D7 and 21, Ang1 and 2 may be
expressed by endothelial and epithelial cells in the tracheal
graft; in allografts where the epithelium is degraded, the
endothelial cells of the developing vessels might be the
source of angiopoietins, in particular in the fibroprolifera-
tive tissue in allografts. This obviously suggests a complex
balance between vessel maturation and regression, sup-
ported by the smaller number of functional vessels in the
tracheal tissue of allografts compared to isografts.
In addition to blood vessel revascularization, we report
here that LYVE1+ lymphatic vessels (endothelial hyaluro-
nan receptor) are located within the subepithelium of the
tracheal tissue and around the cartilage, as well as within
the fibroproliferative tissue of the allografts. The larger
lymphatic vessels (30–300 and >300 lm2) occur more
often in allografts in all these locations; indeed, the largest
vessels (>300 lm2) cannot even be found in isografts at
D21. This is consistent with findings from the HTT in
the omentum, where lymphatic vasculature has been
reported in allograft fibroproliferative tissue (Tikkanen
et al. 2006). Lymphatic vessels are involved in the traffick-
ing of antigen-presenting cells to the graft. We hypothe-
size that the lymphatic supply is involved in the re-
epithelialization in isografts (D3) (Hegab et al. 2012), and
required for the alloreaction in allografts (D21).
We also show that expression of the mucin-type trans-
membrane glycoprotein podoplanin increases and peaks at
D7 in both iso- and allografts. Its precise function is not
yet well understood. It is expressed by the lymphatic
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endothelial cells during lymphangiogenesis, induces platelet
aggregation, which blocks lymphaticovenous connections,
and helps separate the blood and lymphatic vascular sys-
tems (Suzuki-Inoue et al. 2006; Uhrin et al. 2010). Pdpn is
also required for maintaining the segregation of blood and
lymphatic vessels during tissue remodeling (Fu et al. 2008).
In our experiments, however, Pdpn expression did not dif-
fer between iso- versus allografts at D21. This finding sug-
gests that it may be involved in lymphatic vessel
maintenance in the grafts, but not in the size of the lym-
phatic vessels. Further investigation of the lymphatic vascu-
lature in tracheal grafts would be useful for understanding
its role in the pathophysiological processes of OB. Never-
theless, we show for the first time the presence of lymphatic
vessels in tracheal grafts after HTT in the subcutaneous tis-
sue of mice.
Conclusion
This study is the first to clearly demonstrate the vascular-
ization of iso- and allografts and to quantify it by count-
ing the functional blood vessels and lymphatic vessels
after subcutaneous murine HTT. The angiogenic factors
VEGF, Ang1, Ang2, and podoplanin mediate the forma-
tion of the vascular and lymphatic network in the trans-
planted tracheas as OB progresses. Our data thus provide
new information for our understanding of HTT as a
model for OB. This study also sheds light on a new
advantage of this model, in addition to its ease of use,
reproducibility, and viability in the absence of immuno-
suppressive treatment, as a valuable model for performing
proof-of-concept studies in OB development during
chronic lung allograft dysfunction.
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